Ascendis Pharma A/S (ASND)
NASDAQ
Closed
Aug 21, 2026
Day's Range
252.8752 wk Range
186.05Overview - ASND - Ascendis Pharma A/S
Key Statistics
Valuation
Enterprise Value
19.04B
P/E (Trailing)
‪19.37‬
P/E (Forward)
‪26.56‬
PEG Ratio
‪-0.02‬
Price / Sales (TTM)
‪15.86‬
Price / Book
‪9.90‬
EV / EBITDA
‪61.76‬
Profitability
Gross Margin
‪92.89%‬
Profit Margin
‪70.84%‬
Operating Margin
‪64.97%‬
Return on Assets
‪9.58%‬
Return on Equity
‪118.78%‬
Ownership
Shares Outstanding
61.77M
Float
65.64M
Short % of Shares Outstanding
‪6.15%‬
Held by Insiders
‪0.78%‬
Held by Institutions
‪103.32%‬
Price stats
50-Day Avg
‪252.20‬
200-Day Avg
‪229.70‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
19 analysts
Average price target
‪$ 313.87‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ASND - Ascendis Pharma A/S
Peers - ASND - Ascendis Pharma A/S
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+24.84%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.16P/E (Trailing)‪2.14%‬Profit Margin
- ARWRNASDAQArrowhead Pharmaceuticals Inc.12.30BMarket Cap+76.22%52-week change47.10P/E (Trailing)‪-47.79%‬Profit Margin
Profile Summary - ASND - Ascendis Pharma A/S
About
Ascendis Pharma A/S is a biopharmaceutical company that develops and commercializes therapies for patients with unmet medical needs, with a primary focus on endocrinology and rare diseases. Headquartered in Hellerup, Denmark and founded in 2006, the company uses its TransCon technology platform to modify existing drug…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
